Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MYO10

Gene summary for MYO10

Gene summary.

Gene information	Species	Human
	Gene symbol	MYO10
	Gene ID	4651
	Gene name	myosin X
	Gene Alias	MYO10
	Cytomap	5p15.1
	Gene Type	protein-coding
	GO ID	GO:0000902
	UniProtAcc	Q9HD67

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
4651	MYO10	RNA-P6T2-P6T2-4	Human	Lung	IAC	1.78e-04	2.26e-01	-0.0121
4651	MYO10	RNA-P7T1-P7T1-2	Human	Lung	AIS	1.21e-03	4.31e-01	-0.0876
4651	MYO10	RNA-P7T1-P7T1-4	Human	Lung	AIS	2.05e-03	3.72e-01	-0.0809
4651	MYO10	C04	Human	Oral cavity	OSCC	1.15e-26	1.48e+00	0.2633
4651	MYO10	C21	Human	Oral cavity	OSCC	2.49e-38	1.32e+00	0.2678
4651	MYO10	C30	Human	Oral cavity	OSCC	4.14e-44	1.84e+00	0.3055
4651	MYO10	C43	Human	Oral cavity	OSCC	1.01e-16	3.98e-01	0.1704
4651	MYO10	C51	Human	Oral cavity	OSCC	3.87e-16	1.12e+00	0.2674
4651	MYO10	C57	Human	Oral cavity	OSCC	7.58e-18	6.06e-01	0.1679
4651	MYO10	C06	Human	Oral cavity	OSCC	9.44e-06	1.29e+00	0.2699
4651	MYO10	C08	Human	Oral cavity	OSCC	1.01e-19	6.57e-01	0.1919
4651	MYO10	LP15	Human	Oral cavity	LP	3.71e-03	8.93e-01	0.2174
4651	MYO10	NEOLP-3	Human	Oral cavity	NEOLP	1.64e-02	1.89e-01	-0.0191
4651	MYO10	SYSMH1	Human	Oral cavity	OSCC	3.68e-27	6.76e-01	0.1127
4651	MYO10	SYSMH2	Human	Oral cavity	OSCC	8.35e-09	3.66e-01	0.2326
4651	MYO10	SYSMH3	Human	Oral cavity	OSCC	8.25e-28	7.91e-01	0.2442
4651	MYO10	SYSMH5	Human	Oral cavity	OSCC	6.98e-24	7.06e-01	0.0647
4651	MYO10	GSM5252132_BPH389PrGF	Human	Prostate	BPH	1.08e-03	4.15e-01	-0.2247
4651	MYO10	GSM5252133_BPH389PrSF	Human	Prostate	BPH	1.43e-02	4.64e-01	-0.2027
4651	MYO10	047563_1562-all-cells	Human	Prostate	BPH	8.30e-06	3.09e-01	0.0791

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:002260410	Cervix	CC	regulation of cell morphogenesis	84/2311	309/18723	1.00e-12	4.29e-10	84
GO:002240710	Cervix	CC	regulation of cell-cell adhesion	103/2311	448/18723	1.78e-10	2.87e-08	103
GO:004578510	Cervix	CC	positive regulation of cell adhesion	101/2311	437/18723	1.96e-10	3.08e-08	101
GO:00224099	Cervix	CC	positive regulation of cell-cell adhesion	61/2311	284/18723	9.30e-06	2.11e-04	61
GO:00083608	Cervix	CC	regulation of cell shape	38/2311	154/18723	1.86e-05	3.46e-04	38
GO:00307057	Cervix	CC	cytoskeleton-dependent intracellular transport	40/2311	195/18723	7.92e-04	6.99e-03	40
GO:01200328	Cervix	CC	regulation of plasma membrane bounded cell projection assembly	38/2311	186/18723	1.14e-03	9.35e-03	38
GO:00604917	Cervix	CC	regulation of cell projection assembly	38/2311	188/18723	1.40e-03	1.10e-02	38
GO:0022604	Colorectum	AD	regulation of cell morphogenesis	109/3918	309/18723	3.08e-09	2.07e-07	109
GO:0008360	Colorectum	AD	regulation of cell shape	56/3918	154/18723	7.01e-06	1.73e-04	56
GO:0045785	Colorectum	AD	positive regulation of cell adhesion	122/3918	437/18723	2.65e-04	3.28e-03	122
GO:0030705	Colorectum	AD	cytoskeleton-dependent intracellular transport	60/3918	195/18723	7.56e-04	7.59e-03	60
GO:0120032	Colorectum	AD	regulation of plasma membrane bounded cell projection assembly	53/3918	186/18723	8.51e-03	4.97e-02	53
GO:00226041	Colorectum	SER	regulation of cell morphogenesis	89/2897	309/18723	1.51e-09	1.52e-07	89
GO:00083601	Colorectum	SER	regulation of cell shape	43/2897	154/18723	5.47e-05	1.30e-03	43
GO:00457851	Colorectum	SER	positive regulation of cell adhesion	93/2897	437/18723	6.78e-04	9.04e-03	93
GO:01200321	Colorectum	SER	regulation of plasma membrane bounded cell projection assembly	43/2897	186/18723	3.82e-03	3.16e-02	43
GO:0060491	Colorectum	SER	regulation of cell projection assembly	43/2897	188/18723	4.68e-03	3.70e-02	43
GO:00307051	Colorectum	SER	cytoskeleton-dependent intracellular transport	44/2897	195/18723	5.53e-03	4.09e-02	44
GO:00226042	Colorectum	MSS	regulation of cell morphogenesis	103/3467	309/18723	2.70e-10	2.56e-08	103

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0513020	Cervix	CC	Pathogenic Escherichia coli infection	63/1267	197/8465	9.28e-10	2.00e-08	1.19e-08	63
hsa0466612	Cervix	CC	Fc gamma R-mediated phagocytosis	31/1267	97/8465	1.78e-05	1.42e-04	8.40e-05	31
hsa05130110	Cervix	CC	Pathogenic Escherichia coli infection	63/1267	197/8465	9.28e-10	2.00e-08	1.19e-08	63
hsa0466613	Cervix	CC	Fc gamma R-mediated phagocytosis	31/1267	97/8465	1.78e-05	1.42e-04	8.40e-05	31
hsa04666	Colorectum	AD	Fc gamma R-mediated phagocytosis	46/2092	97/8465	9.10e-07	1.22e-05	7.77e-06	46
hsa05130	Colorectum	AD	Pathogenic Escherichia coli infection	79/2092	197/8465	1.05e-06	1.36e-05	8.65e-06	79
hsa046661	Colorectum	AD	Fc gamma R-mediated phagocytosis	46/2092	97/8465	9.10e-07	1.22e-05	7.77e-06	46
hsa051301	Colorectum	AD	Pathogenic Escherichia coli infection	79/2092	197/8465	1.05e-06	1.36e-05	8.65e-06	79
hsa046662	Colorectum	SER	Fc gamma R-mediated phagocytosis	39/1580	97/8465	5.84e-07	9.70e-06	7.04e-06	39
hsa051302	Colorectum	SER	Pathogenic Escherichia coli infection	60/1580	197/8465	3.63e-05	4.31e-04	3.13e-04	60
hsa046663	Colorectum	SER	Fc gamma R-mediated phagocytosis	39/1580	97/8465	5.84e-07	9.70e-06	7.04e-06	39
hsa051303	Colorectum	SER	Pathogenic Escherichia coli infection	60/1580	197/8465	3.63e-05	4.31e-04	3.13e-04	60
hsa051304	Colorectum	MSS	Pathogenic Escherichia coli infection	73/1875	197/8465	1.10e-06	1.48e-05	9.06e-06	73
hsa051305	Colorectum	MSS	Pathogenic Escherichia coli infection	73/1875	197/8465	1.10e-06	1.48e-05	9.06e-06	73
hsa051306	Colorectum	MSI-H	Pathogenic Escherichia coli infection	31/797	197/8465	2.90e-03	2.93e-02	2.46e-02	31
hsa051307	Colorectum	MSI-H	Pathogenic Escherichia coli infection	31/797	197/8465	2.90e-03	2.93e-02	2.46e-02	31
hsa051308	Colorectum	FAP	Pathogenic Escherichia coli infection	62/1404	197/8465	1.37e-07	3.08e-06	1.87e-06	62
hsa046666	Colorectum	FAP	Fc gamma R-mediated phagocytosis	35/1404	97/8465	2.46e-06	4.28e-05	2.60e-05	35
hsa051309	Colorectum	FAP	Pathogenic Escherichia coli infection	62/1404	197/8465	1.37e-07	3.08e-06	1.87e-06	62
hsa046667	Colorectum	FAP	Fc gamma R-mediated phagocytosis	35/1404	97/8465	2.46e-06	4.28e-05	2.60e-05	35

Page: 1 2 3 4

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MYO10

SNV

Missense_Mutation

novel

c.5425N>C

p.Glu1809Gln

p.E1809Q

Q9HD67

protein_coding

tolerated(0.1)

probably_damaging(0.999)

TCGA-3C-AALI-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Poly E

Complete Response

MYO10

SNV

Missense_Mutation

novel

c.4297N>C

p.Glu1433Gln

p.E1433Q

Q9HD67

protein_coding

deleterious(0.01)

probably_damaging(0.999)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

MYO10

SNV

Missense_Mutation

novel

c.4628N>A

p.Pro1543Gln

p.P1543Q

Q9HD67

protein_coding

deleterious(0)

possibly_damaging(0.866)

TCGA-A7-A0DB-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

MYO10

SNV

Missense_Mutation

c.6007N>T

p.Gly2003Trp

p.G2003W

Q9HD67

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-A8-A07B-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO10

SNV

Missense_Mutation

novel

c.452N>G

p.Gln151Arg

p.Q151R

Q9HD67

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-A8-A09Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO10

SNV

Missense_Mutation

novel

c.2806N>T

p.Arg936Trp

p.R936W

Q9HD67

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.98)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO10

SNV

Missense_Mutation

rs769014797

c.266N>T

p.Arg89Ile

p.R89I

Q9HD67

protein_coding

deleterious(0.01)

benign(0.157)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYO10

SNV

Missense_Mutation

c.2906N>C

p.Ser969Thr

p.S969T

Q9HD67

protein_coding

tolerated_low_confidence(0.54)

benign(0)

TCGA-AN-A0XV-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

MYO10

SNV

Missense_Mutation

c.191N>A

p.Gly64Asp

p.G64D

Q9HD67

protein_coding

deleterious(0)

possibly_damaging(0.619)

TCGA-AO-A0J6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

MYO10

SNV

Missense_Mutation

c.5470N>C

p.Glu1824Gln

p.E1824Q

Q9HD67

protein_coding

deleterious(0.01)

probably_damaging(0.999)

TCGA-B6-A0I2-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1